215 related articles for article (PubMed ID: 27293995)
1. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.
Liu X; Zhang P; Martin RC; Cui G; Wang G; Tan Y; Cai L; Lv G; Li Y
Am J Cancer Res; 2016; 6(5):1011-25. PubMed ID: 27293995
[TBL] [Abstract][Full Text] [Related]
2. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
[No Abstract] [Full Text] [Related]
3. Lack of FGF21 promotes NASH-HCC transition
Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
[No Abstract] [Full Text] [Related]
4. Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation.
Zhang Q; Li Y; Liang T; Lu X; Liu X; Zhang C; Jiang X; Martin RC; Cheng M; Cai L
Am J Cancer Res; 2015; 5(5):1762-74. PubMed ID: 26175944
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet.
Singhal G; Kumar G; Chan S; Fisher FM; Ma Y; Vardeh HG; Nasser IA; Flier JS; Maratos-Flier E
Mol Metab; 2018 Jul; 13():56-66. PubMed ID: 29753678
[TBL] [Abstract][Full Text] [Related]
6. Triclosan leads to dysregulation of the metabolic regulator FGF21 exacerbating high fat diet-induced nonalcoholic fatty liver disease.
Yueh MF; He F; Chen C; Vu C; Tripathi A; Knight R; Karin M; Chen S; Tukey RH
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31259-31266. PubMed ID: 33229553
[TBL] [Abstract][Full Text] [Related]
7. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Tillman EJ; Rolph T
Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver.
Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237
[TBL] [Abstract][Full Text] [Related]
10. The role of FGF21 and its analogs on liver associated diseases.
Falamarzi K; Malekpour M; Tafti MF; Azarpira N; Behboodi M; Zarei M
Front Med (Lausanne); 2022; 9():967375. PubMed ID: 36457562
[TBL] [Abstract][Full Text] [Related]
11. FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation.
Keinicke H; Sun G; Mentzel CMJ; Fredholm M; John LM; Andersen B; Raun K; Kjaergaard M
Endocr Connect; 2020 Aug; 9(8):755-768. PubMed ID: 32688339
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
Tucker B; Li H; Long X; Rye KA; Ong KL
Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
[TBL] [Abstract][Full Text] [Related]
13. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.
Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR
Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278
[TBL] [Abstract][Full Text] [Related]
14. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.
Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M
Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251
[TBL] [Abstract][Full Text] [Related]
15. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Liu J; Xu Y; Hu Y; Wang G
Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
[TBL] [Abstract][Full Text] [Related]
16. The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
Schumacher JD; Kong B; Pan Y; Zhan L; Sun R; Aa J; Rizzolo D; Richardson JR; Chen A; Goedken M; Aleksunes LM; Laskin DL; Guo GL
Toxicol Appl Pharmacol; 2017 Sep; 330():1-8. PubMed ID: 28673684
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
Su X; Kong Y; Peng D
Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury.
Desai BN; Singhal G; Watanabe M; Stevanovic D; Lundasen T; Fisher FM; Mather ML; Vardeh HG; Douris N; Adams AC; Nasser IA; FitzGerald GA; Flier JS; Skarke C; Maratos-Flier E
Mol Metab; 2017 Nov; 6(11):1395-1406. PubMed ID: 29107287
[TBL] [Abstract][Full Text] [Related]
19. Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis.
Ye X; Chen Y; Qi J; Zhu S; Wu Y; Xiong J; Hu F; Guo Z; Liang X
Eur J Pharmacol; 2023 Aug; 952():175811. PubMed ID: 37245859
[TBL] [Abstract][Full Text] [Related]
20. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease.
Gaemers IC; Stallen JM; Kunne C; Wallner C; van Werven J; Nederveen A; Lamers WH
Biochim Biophys Acta; 2011 Apr; 1812(4):447-58. PubMed ID: 21216282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
